Marksans Pharma Share Price
Marksans Pharma Share Price Today
As of 5 Jul 2026, Marksans Pharma share price is ₹264.45. The stock opened at ₹268.00, compared to its previous close of ₹267.20. During today's trading session, Marksans Pharma share price moved in the range of ₹262.40 to ₹269.85, with an average price of ₹266.13 for the day. Looking at its last 52-week, the stock has touched a low of ₹155.00 and a high of ₹278.80. On the performance front, Marksans Pharma share price has increased by 45.15% over the last six months and is up 1.91% on a year-on-year basis.
Marksans Pharma Returns Calculator
Marksans Pharma Shareholder Returns
Marksans Pharma Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Marksans Pharma Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹2,622.85 | ₹2,177.41 | ₹1,852.14 | ₹1,490.84 |
| Other Income | ₹70.38 | ₹50.42 | ₹59.31 | ₹41.85 |
| Total Revenue | ₹2,693.22 | ₹2,227.83 | ₹1,911.45 | ₹1,532.69 |
| Total Expenses | ₹2,189.25 | ₹1,804.30 | ₹1,573.80 | ₹1,285.18 |
| Profit Before Tax | ₹503.97 | ₹423.53 | ₹337.65 | ₹247.51 |
| Tax | ₹121.35 | ₹108.63 | ₹72.33 | ₹60.70 |
| Profit After Tax | ₹382.62 | ₹314.90 | ₹265.32 | ₹186.81 |
| EPS - Basic | ₹8.40 | ₹6.92 | ₹6.41 | ₹4.51 |
| EPS - Diluted | ₹8.40 | ₹6.92 | ₹6.41 | ₹4.51 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹503.97 | ₹423.53 | ₹337.65 | ₹247.51 |
| Income before WC changes | ₹573.34 | ₹478.95 | ₹411.89 | ₹282.82 |
| Change in Assets | -₹290.68 | -₹178.88 | -₹94.69 | -₹129.19 |
| Change in Liabilities | ₹49.91 | ₹52.69 | -₹16.78 | ₹18.49 |
| Change in WC | -₹240.77 | -₹126.19 | -₹111.47 | -₹110.70 |
| Cash flow from Operations | ₹206.66 | ₹230.41 | ₹237.41 | ₹99.26 |
| Cash flow from Investing | -₹49.01 | -₹140.84 | -₹259.21 | -₹84.39 |
| Cash flow from Financing | -₹65.15 | -₹68.73 | ₹197.83 | ₹79.51 |
| Total Cash Flow | ₹92.51 | ₹20.84 | ₹176.03 | ₹94.38 |
| Cash (Start of the year) | ₹403.28 | ₹382.44 | ₹206.41 | ₹112.03 |
| Cash (End of the year) | ₹495.79 | ₹403.28 | ₹382.44 | ₹206.41 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,035.51 | ₹818.46 | ₹515.09 | ₹438.90 |
| Current Assets | ₹2,204.12 | ₹1,862.49 | ₹1,675.30 | ₹1,201.20 |
| Total Assets | ₹3,239.63 | ₹2,680.95 | ₹2,190.39 | ₹1,640.10 |
| Current Liabilities | ₹477.34 | ₹389.85 | ₹340.99 | ₹356.22 |
| Net Current Asset | ₹1,726.78 | ₹1,472.64 | ₹1,334.31 | ₹844.98 |
| Non-Current Liabilities | ₹272.91 | ₹205.20 | ₹84.33 | ₹60.91 |
| Equity Capital | ₹2,489.38 | ₹2,085.91 | ₹1,765.07 | ₹1,222.97 |
| Total Equity & Liabilities | ₹3,239.63 | ₹2,680.95 | ₹2,190.39 | ₹1,640.10 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,174.37 | ₹853.27 | ₹655.20 | ₹658.29 |
| Other Income | ₹69.83 | ₹62.07 | ₹60.48 | ₹42.25 |
| Total Revenue | ₹1,244.21 | ₹915.35 | ₹715.69 | ₹700.54 |
| Total Expenses | ₹1,000.95 | ₹743.45 | ₹583.65 | ₹566.03 |
| Profit Before Tax | ₹243.26 | ₹171.89 | ₹132.04 | ₹134.51 |
| Tax | ₹54.99 | ₹38.13 | ₹29.17 | ₹30.52 |
| Profit After Tax | ₹188.27 | ₹133.76 | ₹102.87 | ₹103.99 |
| EPS - Basic | ₹4.15 | ₹2.95 | ₹2.48 | ₹2.54 |
| EPS - Diluted | ₹4.15 | ₹2.95 | ₹2.48 | ₹2.54 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹243.26 | ₹171.89 | ₹132.04 | ₹134.51 |
| Income before WC changes | ₹235.67 | ₹155.50 | ₹142.94 | ₹126.57 |
| Change in Assets | -₹212.02 | -₹145.87 | -₹116.44 | -₹85.82 |
| Change in Liabilities | ₹53.91 | ₹63.19 | ₹56.84 | ₹47.05 |
| Change in WC | -₹158.11 | -₹82.68 | -₹59.60 | -₹38.77 |
| Cash flow from Operations | ₹31.02 | ₹34.05 | ₹51.73 | ₹55.97 |
| Cash flow from Investing | ₹17.24 | -₹114.22 | -₹194.62 | -₹128.06 |
| Cash flow from Financing | -₹29.92 | -₹26.22 | ₹210.02 | ₹70.86 |
| Total Cash Flow | ₹18.34 | -₹106.38 | ₹67.12 | -₹1.23 |
| Cash (Start of the year) | ₹41.93 | ₹148.31 | ₹81.19 | ₹82.42 |
| Cash (End of the year) | ₹60.27 | ₹41.93 | ₹148.31 | ₹81.19 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹673.08 | ₹568.33 | ₹431.10 | ₹375.75 |
| Current Assets | ₹1,082.22 | ₹947.70 | ₹913.76 | ₹589.86 |
| Total Assets | ₹1,755.30 | ₹1,516.04 | ₹1,344.86 | ₹965.61 |
| Current Liabilities | ₹345.64 | ₹272.44 | ₹216.54 | ₹166.53 |
| Net Current Asset | ₹736.59 | ₹675.27 | ₹697.22 | ₹423.34 |
| Non-Current Liabilities | ₹26.18 | ₹20.90 | ₹17.00 | ₹14.41 |
| Equity Capital | ₹1,383.49 | ₹1,222.71 | ₹1,111.32 | ₹784.67 |
| Total Equity & Liabilities | ₹1,755.30 | ₹1,516.04 | ₹1,344.86 | ₹965.61 |
About Marksans Pharma
Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.
The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.
Business operations
Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.
In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.
Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.
Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.
The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.
Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.
In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.
Marksans Pharma Financial Highlights
- Revenue: Marksans Pharma reported revenue of ₹3,033.47 crore in FY26 vs ₹2,689.18 crore in FY25. It showed an increase of 12.80% on a yearly basis.
- Operating Profit: Marksans Pharma reported an operating profit of ₹560.56 crore in FY26 vs ₹503.97 crore in FY25. It showed an increase of 11.23% on a year-on-year basis.
- Net Profit: Marksans Pharma reported a net profit of ₹420.06 crore in FY26 vs ₹382.62 crore in FY25. It showed an increase of 9.79% on a yearly basis.
Marksans Pharma Quarterly Result Highlights
- Marksans Pharma reported revenue of ₹891.28 crore in Mar 2026, compared with ₹774.57 crore in Dec 2025, representing an increase of 15.07% on a quarter-on-quarter (QoQ) basis.
- Marksans Pharma reported an operating profit of ₹200.00 crore in Mar 2026, compared with ₹150.62 crore in Dec 2025, representing an increase of 32.78% on a quarter-on-quarter (QoQ) basis.
- Marksans Pharma reported a profit of ₹149.03 crore in Mar 2026, compared with ₹113.69 crore in Dec 2025, reflecting an increase of 31.08% on a QoQ basis.
- The earnings per share (EPS) of Marksans Pharma stood at ₹8.40 during Mar 2026.
Similar Stocks
FAQs on Marksans Pharma Share Price
What is Marksans Pharma share price today?
Marksans Pharma share price is ₹264.45 as on 03 Jul, 2026, 15:47 IST.
How has the Marksans Pharma share price performed in the past?
In the last 1 year, Marksans Pharma delivered a return of 1.91%. The Marksans Pharma share price hit a high of ₹278.80 and low of ₹155.00.
How much is the Mutual Fund shareholding in Marksans Pharma shares?
The Mutual Fund Shareholding in Marksans Pharma was 4.66% at the end of Mar 2026.
What is the the 52-week high and low of Marksans Pharma shares ?
The 52-week high and low of Marksans Pharma share is ₹278.80 and ₹155.00 as of 03 Jul, 2026.
What is the market cap of Marksans Pharma?
The market capitalisation of Marksans Pharma is ₹12,101.70 Crores as on 03 Jul, 2026.
What are the stock symbols of Marksans Pharma?
The stock symbol of Marksans Pharma is MARKSANS on the NSE, 524404 on the BSE, and the ISIN is INE750C01026.
What was yesterday's closing price of Marksans Pharma shares ?
Marksans Pharma shares closed yesterday at ₹267.20 on NSE & ₹267.05 on BSE
How to buy Marksans Pharma shares?
To buy Marksans Pharma shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Marksans Pharma shares on Holidays?
No, shares of Marksans Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Marksans Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Marksans Pharma?
The PE and PB ratio of Marksans Pharma is 28.81 and 4 respectively, as on 03 Jul, 2026, 15:47 IST.